Edition:
United Kingdom

Juno Therapeutics Inc (JUNO.OQ)

JUNO.OQ on NASDAQ Stock Exchange Global Select Market

45.75USD
8:59pm GMT
Change (% chg)

$-4.49 (-8.94%)
Prev Close
$50.24
Open
$50.38
Day's High
$50.59
Day's Low
$45.26
Volume
1,933,370
Avg. Vol
707,143
52-wk High
$63.33
52-wk Low
$17.52

Chart for

About

Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to... (more)

Overall

Beta: --
Market Cap(Mil.): $4,869.33
Shares Outstanding(Mil.): 111.66
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

BRIEF-Juno Therapeutics Signs Licensing Agreements With Lilly, Oncotracker, And Fred Hutchinson Cancer Research Center

* JUNO THERAPEUTICS SIGNS LICENSING AGREEMENTS WITH LILLY, ONCOTRACKER, AND FRED HUTCHINSON CANCER RESEARCH CENTER TO ADVANCE ITS BCMA-DIRECTED ENGINEERED T CELL PROGRAM IN MULTIPLE MYELOMA WITH GAMMA SECRETASE INHIBITION

06 Dec 2017

BRIEF-Juno Therapeutics reports Q3 adjusted loss per share ‍$0.73​

* Juno Therapeutics reports third quarter 2017 financial results

01 Nov 2017

BRIEF-Juno Therapeutics and Trianni sign licensing agreement for use of Trianni Transgenic Mouse platform

* Trianni and Juno Therapeutics sign licensing agreement for use of Trianni Transgenic Mouse platform

18 Oct 2017

BRIEF-Juno Therapeutics prices $250 million follow-on offering

* Juno Therapeutics- Announced pricing of its follow-on public offering of 6.1 million shares of its common stock at a price to public of $41.00 per share Source text for Eikon: Further company coverage:

22 Sep 2017

BRIEF-Juno Therapeutics files for offering of common stock aggregate offering price of $225 mln - SEC Filing‍​

* Juno Therapeutics Inc - Files for offering of common stock; aggregate offering price of $225 million - SEC Filing‍​ Source text for Eikon: Further company coverage:

20 Sep 2017

BRIEF-Juno Therapeutics qtrly ‍loss per share $0.96

* Juno Therapeutics reports second quarter 2017 financial results

03 Aug 2017

Earnings vs. Estimates